Related Experiment Video
Updated: Aug 19, 2025
A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
Published on: March 17, 2023
Recent advances in NIR-II fluorescence based theranostic approaches for glioma
Jiaying Li1,2, Jue Ling2, Chaoyi Yao3
1Department of Nosocomial Infection Management, Nantong Third People's Hospital Affiliated to Nantong University, Nantong, Jiangsu, China.
Abstract:
Gliomas are among the most common malignant tumors in the central nervous system and lead to poor life expectancy. However, the effective treatment of gliomas remains a considerable challenge. The recent development of near infrared (NIR) II (1000-1700 nm) theranostic agents has led to powerful strategies in diagnosis, targeted delivery of drugs, and accurate therapy. Because of the high capacity of NIR-II light in deep tissue penetration, improved spatiotemporal resolution can be achieved to facilitate the in vivo detection of gliomas via fluorescence imaging, and high contrast fluorescence imaging guided surgery can be realized. In addition to the precise imaging of tumors, drug delivery nano-platforms with NIR-II agents also allow the delivery process to be monitored in real-time. In addition, the combination of targeted drug delivery, photodynamic therapy, and photothermal therapy in the NIR region significantly improves the therapeutic effect against gliomas. Thus, this mini-review summarizes the recent developments in NIR-II fluorescence-based theranostic agents for glioma treatment.
Insights
Near-infrared II (NIR-II) theranostic agents offer advanced glioma diagnosis and treatment. These agents enable precise fluorescence imaging and targeted drug delivery for improved glioma therapy.
Area of Science:
- Neuro-oncology
- Biomedical Engineering
- Nanotechnology
Background:
- Gliomas are aggressive central nervous system tumors with poor prognoses.
- Effective glioma treatment remains a significant clinical challenge.
- Near-infrared II (NIR-II) theranostic agents present novel therapeutic and diagnostic strategies.
Purpose of the Study:
- To review recent advancements in NIR-II fluorescence-based theranostic agents for glioma treatment.
- To highlight the role of NIR-II agents in enhancing glioma diagnosis and therapy.
- To discuss the integration of imaging, drug delivery, and therapy using NIR-II agents.
Main Methods:
- Review of recent scientific literature on NIR-II theranostic agents for gliomas.
- Analysis of NIR-II fluorescence imaging capabilities for *in vivo* glioma detection.
- Evaluation of drug delivery nano-platforms and combination therapies utilizing NIR-II agents.
Main Results:
- NIR-II light enables deep tissue penetration for enhanced *in vivo* glioma imaging and surgical guidance.
- NIR-II agents facilitate real-time monitoring of drug delivery processes.
- Combination therapies (drug delivery, photodynamic, photothermal) with NIR-II agents show improved glioma treatment efficacy.
Conclusions:
- NIR-II theranostic agents are powerful tools for improving glioma diagnosis and treatment.
- These agents offer precise imaging, targeted drug delivery, and effective multimodal therapies.
- Further development of NIR-II agents holds significant promise for advancing glioma care.
